Streetbeat News

Analyst Ratings

JNJ

Significant bearish options activity has been detected in Johnson & Johnson (NYSE:JNJ), with a sentiment split of 12% bullish and 87% bearish among big-money traders. Unusual options trades were spotted, with 2 puts and 6 calls totaling $401,093. Projected price targets range from $100 to $155. The company is preparing to divest its consumer group under the name Kenvue in 2023. JNJ's current stock price is $156.04, with neutral RSI indicators and an earnings announcement expected in 25 days. Analyst ratings vary, with an average target price of $175.5.

Portfolio Pulse from Benzinga Insights

December 29, 2023 | 5:46 pm

HLIT

Rosenblatt analyst Steve Frankel has reiterated a Buy rating on Harmonic (NASDAQ:HLIT) and maintained the $18 price target for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

December 29, 2023 | 5:36 pm

UBER

Uber shares have declined following a downgrade by Nomura from Buy to Neutral.

Portfolio Pulse from Bill Haddad

December 29, 2023 | 5:23 pm

LYFT

Lyft Inc.'s stock (LYFT) is trading lower following a downgrade by Nomura from 'Neutral' to 'Reduce'.

Portfolio Pulse from Bill Haddad

December 29, 2023 | 5:22 pm

TRIP

Ascendiant Capital has reaffirmed its Buy rating on TripAdvisor (NASDAQ:TRIP) and increased its price target from $27.00 to $30.00. TripAdvisor's shares have risen 0.73% to $21.48 recently. The new price target suggests a potential upside of 39.63%. TripAdvisor is a leading travel metasearch company with a diverse revenue stream from its hotel, experiences, and dining brands.

Portfolio Pulse from Benzinga Insights

December 29, 2023 | 5:00 pm

CTSO

HC Wainwright & Co. downgraded CytoSorbents (NASDAQ:CTSO) from a previous rating to Neutral and slashed the price target from $5.50 to $1.00. Following the downgrade, CTSO shares dropped by 5.07% to $1.03. The new price target suggests a further potential decline of 2.91%. CytoSorbents specializes in blood purification technology for critical care and cardiac surgery.

Portfolio Pulse from Benzinga Insights

December 29, 2023 | 5:00 pm

VTSI

Lake Street has reaffirmed its Buy rating on VirTra (NASDAQ:VTSI) and increased its price target from $9.00 to $13.00. VirTra's stock has risen 1.97% in the last 24 hours to $9.32 per share. The new price target suggests a potential upside of 39.48% from the current price. VirTra specializes in the development and sale of force training simulators for law enforcement, military, and commercial markets globally.

Portfolio Pulse from Benzinga Insights

December 29, 2023 | 5:00 pm

CCL

Macquarie has reaffirmed its Outperform rating on Carnival (NYSE:CCL) and increased its price target from $16.00 to $22.00. Carnival's stock is currently trading at $18.75, up 0.4% over the last 24 hours. The new price target suggests a potential upside of 17.36% from the current price. Carnival is the largest global cruise company and has recovered to its pre-COVID guest levels in 2023.

Portfolio Pulse from Benzinga Insights

December 29, 2023 | 5:00 pm

UCBI

Piper Sandler has maintained a Neutral rating on United Community Banks (NASDAQ:UCBI) and increased its price target from $27.00 to $28.00. Despite this, UCBI shares have declined by 0.74% to $29.71, which is above the new target. The bank operates through its subsidiary, Union Community Bank, with a focus on community banking services across Georgia, Tennessee, and the Carolinas.

Portfolio Pulse from Benzinga Insights

December 29, 2023 | 5:00 pm

BSX

Boston Scientific (NYSE:BSX) has been rated by 8 analysts over the last three months, with a mix of bullish and somewhat bullish opinions. The average 12-month price target is now $63.00, up from $60.62, with a high estimate of $66.00 and a low of $60.00. Analysts from firms like BTIG, Wells Fargo, Truist Securities, TD Cowen, Morgan Stanley, Canaccord Genuity, and Needham have maintained or adjusted their ratings and price targets. Boston Scientific specializes in less invasive medical devices and has a strong market presence with a high market cap and revenue growth, but faces challenges in ROE and ROA.

Portfolio Pulse from Benzinga Insights

December 29, 2023 | 5:00 pm